Intended Use
The kit is intended for serological diagnosis of diseases associated with HHV–6 infection, such as exanthema subitum, acute respiratory illnesses, diarrhoea with fever and febrile seizures in infants, heterophile antibody-negative infectious mononucleosis in children, also interstitial pneumonia, encephalitis, meningitis, hepatitis and aplastic anemia in immunodeficient patients. The presence of IgM anti-HHV-6 antibody indicates ongoing or recent active infection. The test does not differentiate between HHV-6 subtype A and B. The test is intended for HHV-6-specific IgM determination in human sera. The test should be supplemented with the determination of HHV-6-specific IgG antibodies (ELISAanti-HHV-6 IgG).
Storage
1. Store the kit and the kit reagents at +2 to +10°C, in a dry place and protected from the light.
2. Store unused strips in the sealable pouch and keep the desiccant inside.
3. Store serum samples at +2 to +10°C up to one week. For longer period make aliquots and keep them at -
20°C. Avoid repeated thawing and freezing.
4. Do not store diluted samples. Always prepare fresh.
5. Kits are shipped in cooling bags, the transport time of 72 hours have no influence on expiration.
6. If you find damage at any part of the kit, please inform the manufacturer immediately.
7. Expiration date is indicated at the ELISA kit label and at all reagent labels.
Performance Characteristics
The kit is intended for the qualitative and semiquantitative detection of anti-HHV-6 IgM antibodies against Herpes virus type 6 (HHV6) in human serum. Suitable specimens are serum (heparinised) samples obtained by standard laboratory techniques.
Validity of the test
The absorbance value of the Dilution buffer (DIL PLUS = reaction background) should be < 0.250.
The OD values of the standards / control sera and the ratio of the OD values of the standards PC / CAL should be within the ranges stated in the Quality Control Certificate of the lot.
TGFβ links EBV to multisystem inflammatory syndrome in children
Goetzke, C. C., Massoud, M., Frischbutter, S., Guerra, G. M., Ferreira-Gomes, M., Heinrich, F., von Stuckrad, A. S. L., Wisniewski, S., Licha, J. R., Bondareva, M., Ehlers, L., Khaldi-Plassart, S., Javouhey, E., Pons, S., Trouillet-Assant, S., Ozsurekci, Y., Zhang, Y., Poli, M. C., Discepolo, V., Lo Vecchio, A., … Mashreghi, M. F.
Applications: ELISA
Reactive species: Human
"Abstract: In a subset of children and adolescents, SARS-CoV-2 infection induces a severe acute hyperinflammatory shock termed multisystem inflammatory syndrome in children (MIS-C) at four to eight weeks after infection. MIS-C is characterized by a specific T cell expansion and systemic hyperinflammation. The pathogenesis of MIS-C remains largely unknown. Here we show that acute MIS-C is characterized by impaired reactivation of virus-reactive memory T cells, which depends on increased serum levels of the cytokine TGFβ resembling those that occur during severe COVID-19. This functional impairment in T cell reactivity is accompanied by the presence of TGFβ-response signatures in T cells, B cells and monocytes along with reduced antigen-presentation capabilities of monocytes, and can be reversed by blocking TGFβ. Furthermore, T cell receptor repertoires of patients with MIS-C exhibit expansion of T cells expressing TCRVβ21.3, resembling Epstein-Barr virus (EBV)-reactive T cell clones capable of eliminating EBV-infected B cells. Additionally, serum TGFβ in patients with MIS-C can trigger EBV reactivation, which is reversible with TGFβ blockade. Clinically, the TGFβ-induced defect in T cell reactivity correlates with a higher EBV seroprevalence in patients with MIS-C compared with age-matched controls, along with the occurrence of EBV reactivation. Our findings establish a connection between SARS-CoV-2 infection and COVID-19 sequelae in children, in which impaired T cell cytotoxicity triggered by TGFβ overproduction leads to EBV reactivation and subsequent hyperinflammation."
Article snippet: Serum IgG-antibody levels against HSV-1 (*), HSV2 (*), EBNA1 (*), CMV (*), HHV-6 (*) and AdV (Creative Diagnostics, DEIA2382) and serum IgM antibody levels against HSV-1/2 (*), EBNA1 (*), CMV (*), HHV-6 (Creative Diagnostics, DEIABL57) and AdV (Creative Diagnostics, DEIA1767) were measured in first serum samples obtained from patients according to manufacturer’s manuals. 
Figure 1. EBV and CMV seroprevalences, but not HHV-6 or HSV-1, were markedly increased compared with age-matched controls.
COA
Publication 
Loading ......
